Patents by Inventor Rachel Humphrey

Rachel Humphrey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY IN A COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220306745
    Abstract: The invention relates generally to use of a combination therapy of an activatable anti-PDL1 antibody and an anti-CTLA-4 antibody for the treatment of cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Inventors: Rachel Humphrey, Matthias Will, Yifah Yaron
  • USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY IN A NEOADJUVANT COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220296692
    Abstract: The invention relates generally to use of a neoadjuvant combination therapy of an activatable anti-PDL1 antibody and an anti-CTLA-4 antibody for the treatment of cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 22, 2022
    Inventors: Rachel Humphrey, Matthias Will, Yifah Yaron
  • ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20220162332
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 10, 2021
    Publication date: May 26, 2022
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220023439
    Abstract: Provided herein are activatable antibodies that when activated specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 1, 2019
    Publication date: January 27, 2022
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan A. TERRETT, Annie Yang WEAVER, Matthias WILL
  • Activatable anti-PDL1 antibodies, and methods of use thereof
    Patent number: 11168144
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: November 9, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210100913
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 21, 2020
    Publication date: April 8, 2021
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan TERRETT, Annie Yang WEAVER, Matthias WILL
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190117789
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: August 30, 2018
    Publication date: April 25, 2019
    Inventors: LORI CARMAN, RACHEL HUMPHREY, W. MICHAEL KAVANAUGH, JONATHAN TERRETT, ANNIE YANG WEAVER, MATTHIAS WILL
  • ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190016814
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 31, 2018
    Publication date: January 17, 2019
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski
  • Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
    Publication number: 20060247186
    Abstract: This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.
    Type: Application
    Filed: July 5, 2006
    Publication date: November 2, 2006
    Inventors: Christopher Carter, Neil Gibson, Barbara Hibner, Rachel Humphrey, Pamela Trail, Patrick Vincent, Yifan Zhai